Please login to the form below

Not currently logged in
Email:
Password:

Lilly to run two Alzheimer's trials

Eli Lilly and Company is to begin enrolling patients in two trials investigating a potential treatment to delay the progression of Alzheimer's

Eli Lilly and Company is to begin enrolling patients in two phase III clinical trials investigating a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

The identical, multi-centred, randomised, double-blind, placebo-controlled trials will enrol a total of 2,000 patients aged over 55, from over 16 countries. The trials, known as Expedition and Expedition 2, will examine solanezumab compared with a placebo over a treatment period of 18 months. Patients will be permitted to continue taking any treatments for the symptoms of the disease during their participation in the trials.

"Current therapies available to treat Alzheimer's disease may help with symptoms, but they haven't been proven to change the disease progression," said Dr Eric Siemers, medical director, Alzheimer's disease research for Eli Lilly and Company. "Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path towards a treatment that may slow the rate of progression of Alzheimer's disease."

The Expedition trial will be conducted in Argentina, Brazil, Canada, Japan, and United States. Expedition 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States.

21st May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics